The large scale implementation of the Indian government’s Revised National TB Control Program (RNTCP) (sometimes known as RNTCP 1) was started in 1997. The RNTCP was then expanded across India until the entire nation was covered by the RNTCP in March 2006. At this time the RNTCP also became known as RNTCP II. RNTCP II was designed to consolidate the gains achieved in RNTCP I, and to initiate services to address TB/HIV, MDR-TB and to extend RNTCP to the private sector.
RNTCP uses the World Health Organisation (WHO) recommended Directly Observed Treatment Short Course (DOTS) strategy and reaches over a billion people in 632 districts/reporting units. The RNTCP is responsible for carrying out the Government of India five year TB National Strategic Plans.
With the RNTCP both diagnosis and treatment of TB are free. There is also, at least in theory, no waiting period for patients seeking treatment and TB drugs.
The initial objectives of the RNTCP in India were:
New sputum positive patients are those people who have never received TB treatment before, or who have taken TB drugs for less than a month. They have also had a positive result to a sputum test, which diagnoses them as having TB.1Mukherjee, A “Outcomes of different subgroups of smear-positive retreatment patients under RNTCP in rural West Bengal, India”, Rural and Remote Health www.ncbi.nlm.nih.gov/pubmed/19260766
There had been a number of five year National Strategic Plans (NSP)s since the start of the RNTCP. The NSP 2012 – 2017 had the aim of achieving universal access to quality diagnosis and treatment. Before this there was little treatment available through the RNTCP for the treatment of drug resistant TB.
A number of significant improvements were made during the five years of the plan. These included:
Complete geographical coverage for diagnostic and treatment services for multi-drug resistant TB was achieved in 2013. A total of 93,000 people with MDR TB were diagnosed and had been given treatment for drug resistant TB by 2015. Also, the National AIDS Control Organisation (NACO) had collaborated with the RNTCP and had made HIV-TB collaboration effective. Most TB patients registered by the RNTCP were receiving HIV screening and 90% of HIV positive TB patients were receiving anti-retroviral treatment.
A government order in May 2012 made it compulsory for health care providers to notify every TB case diagnosed. This was done with the aim of improving the collection of patient care information. It meant that in future all private doctors, caregivers and clinics treating a TB patient had to report every case of TB to the government.
Comments made in response to this move included concerns about enforcement of notification by private practioners;
“This is definitely a positive step forward. But, I am skeptical about the practical possibility in implementing the policy. Most private practioners consider themselves unaccountable to the government. .. The government should be clear about the action that will be taken in case of non compliance of the private practioners.”
There was also concern about whether when people are referred to the RNTCP from the private sector there would be a good enough service, and whether in practice TB treatment would be available.
In June 2012 the GoI prohibited the import and sale of sero-diagnostic tests for TB. It is now believed that this has saved countless people from having inaccurate results.
The Central TB Division developed a case based and web based system called “Nikshay”. This helped with the reporting of all TB cases. It was scaled up nationally.
The Standards for TB Care in India was also developed and it was published in 2014. The Standards describe what should be done, and the TB treatment and care that should be provided throughout India, including what should be provided in the private sector.
The overall budget required in 2012 – 2017 to achieve the Universal Access vision, to save 750,000 lives from TB, and to control MDR TB, was estimated to be Rs. 5825 crore ($1.17 billion) over the period 2012 – 2017. However, the Planning Commission of India only approved Rs. 4500 crore ($900 million). These budget cuts were widely criticised and in January 2015 a warning letter was submitted to the government signed by TB officers of all states and Union territories. One doctor said:
“There is always a shortage of TB drugs, lack of labs, slow diagnostic tools, inadequate management of treatment and lack of trained personnel. Moreover, since we have failed to give the existing staff their salary dues they are demoralised” 2Srivastava, K, “TB epidemic looms large with Rs 2,000 crore fund cut, erred policy”, dna, 10 January, 2015 www.dnaindia.com/
Meanwhile the Joint TB Monitoring mission (JMM) of the RNTCP had brought together a number of national and international experts and organisations in 2014. They were to generally review the progress, challenges, plans and efforts of the RNTCP to control TB. The implementation of the NSP 2012 – 2017 was one of the areas looked at.
The JMM acknowledged India’s remarkable achievements in TB control over the previous ten years. This included testing more than 80 million people, detecting and treating 15 million TB patients, and saving millions of lives as a result of the efforts of the RNTCP. However, they also said that overall:
“the implementation of the NSP for 2012 – 2017 is generally not on track: projected increases in case detection by the RNTCP have not occurred, vital procurements are delayed and many planned activities have not been implemented. Also, of the recommendations made by the JMM 2012, about two thirds have not been fully implemented.”
The report gave extensive recommendations for each part of the report, and these included:
Towards the end of the period of the plan, and despite the improvements that had already been made:
There had continued to be concern about the standard of care provided in the private sector. Delays in diagnosis, the use of multiple non standard regimens for inappropriate lengths of time, the lack of a way to ensure the full course of treatment was being taken, and the recording of treatment outcomes were just some of the issues.
So in 2016 the RNTCP published revised technical and operational guidance. The new guidelines, the RNTCP Technical and Operational Guidelines for Tuberculosis Control in India 2016, did not replace the previous guidance (the Standards of TB Care in India), but they provide updated recommendations. They also make it absolutely clear that the guidance applies to the private sector as well as the public sector.
The strategic vision of the RNTCP is to lay down guidelines and norms for TB care in the country. So the principle of the RNTCP is that they should extend public services to privately managed patients.
For diagnosis the GoI set up more than 600 CB-NAAT laboratories, and enhanced their capacity with highly sensitive diagnostic services. CB-NAAT is the name given in India to Cartridge Based Nucleic Acid Amplification tests such as Genexpert and TrueNat.
In 2017 it was announced that the national goal was now the elimination of TB in India by 2025. At the same time the launch took place of the next 5 year plan, the NSP 2017 – 2025.
There is much more about the National Strategic Plan 2017 – 2025
Would you like to send us a comment about this page?
2015 report on Indian Revised National TB Control Programme from Joint Monitoring Mission www.tbcindia.nic.in
Revised National Tuberculosis Control Programme National Strategic Plan NSP-2012-2017
Standards for TB Care in India Standards TB Care India
TB India 2017 Revised National TB Control Programme Annual Status Report, New Delhi, 2017 TB India 2017 TB India 2017
[ + ]
|1.||↑||Mukherjee, A “Outcomes of different subgroups of smear-positive retreatment patients under RNTCP in rural West Bengal, India”, Rural and Remote Health www.ncbi.nlm.nih.gov/pubmed/19260766|
|2.||↑||Srivastava, K, “TB epidemic looms large with Rs 2,000 crore fund cut, erred policy”, dna, 10 January, 2015 www.dnaindia.com/|